知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

102 条记录 (耗时 0.024 秒)

    Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity
    24.
    发明申请
    Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity 失效
    通过测定lasp-1免疫反应性来诊断炎性疾病和感染的方法

    公开(公告)号：US20060029990A1

    公开(公告)日：2006-02-09

    申请号：US10511758

    申请日：2003-04-15

    申请人： Andreas Bergmann ,  Christina Fischer-Schulz ,  Joachim Struck

    发明人： Andreas Bergmann ,  Christina Fischer-Schulz ,  Joachim Struck

    IPC分类号： G01N33/53 ,  G01N33/537 ,  G01N33/543

    CPC分类号： G01N33/566 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2800/26

    摘要： Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.

    摘要翻译： 用于早期诊断和诊断的方法，用于预测和评估炎性疾病和感染，特别是脓毒症样全身感染和阿尔茨海默氏病的严重性和治疗伴随监测，其中蛋白质LASP- 1（SEQ ID NO：1）或蛋白质LAP-1（SEQ ID NO：16）或这些蛋白质之一的游离和/或蛋白结合形式的免疫反应性片段优选作为免疫反应性 生物流体或任选的组织样品，并且根据存在和/或数量的炎症性疾病或感染的治疗的存在，预期进程，严重程度或成功性得出结论 的蛋白质。

    Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
    25.
    发明授权
    Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin 有权
    通过确定降钙素原的水平，对患有原发性非传染性疾病的患者进行抗生素治疗的风险评估

    公开(公告)号：US09046532B2

    公开(公告)日：2015-06-02

    申请号：US13264252

    申请日：2010-04-14

    申请人： Andreas Bergmann ,  Joachim Struck

    发明人： Andreas Bergmann ,  Joachim Struck

    IPC分类号： G01N33/00 ,  G01N33/74

    CPC分类号： G01N33/74 ,  G01N2333/585 ,  G01N2800/32 ,  G01N2800/325

    摘要： A diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic, as well as a kit for performing the method and methods of treatment based thereon.

    摘要翻译： 用于鉴定患有可能通过向所述受试者施用抗生素诱导的不利结果的风险增加的主要非传染性疾病的受试者的诊断方法，包括测定降钙素原（PCT）水平或 片段或其在来自所述受试者的体液样品中具有至少12个氨基酸残基的长度的前体或片段以及所确定的水平与通过施用抗生素诱导的潜在风险的相关性，以及 用于执行基于其的处理方法和方法的试剂盒。

    Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method
    27.
    发明授权
    Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method 有权
    用于确定用于医学诊断目的的内皮素形成的方法，以及用于进行这种方法的抗体和试剂盒

    公开(公告)号：US08450463B2

    公开(公告)日：2013-05-28

    申请号：US13398211

    申请日：2012-02-16

    申请人： Andreas Bergmann ,  Joachim Struck

    发明人： Andreas Bergmann ,  Joachim Struck

    IPC分类号： C07K16/00

    CPC分类号： C07K16/00 ,  G01N33/57488 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/5754 ,  Y10S435/975

    摘要： Described herein is an in vitro method for the determination of the formation of endothelins in serious diseases, in particular cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient, in which relatively long-lived peptide fragments of the processed primary prepro- or proendothelins are determined which contain neither the actual biologically active endothelin nor its direct precursor big endothelin. In particular, disclosed are antibodies and kits for selectively detecting these fragments.

    摘要翻译： 本文描述的是用于测定人类患者的全血，血浆或血清中严重疾病，特别是心血管疾病，炎症，败血症和癌症中内皮素形成的体外方法，其中相对长寿的肽片段 的被处理的原始前原或前内皮素被确定为既不含实际的生物活性内皮素也不包含其直接前体大内皮素。 特别地，公开了用于选择性检测这些片段的抗体和试剂盒。

    Diagnosis and risk stratification by determining the marker CT-proADM
    28.
    发明授权
    Diagnosis and risk stratification by determining the marker CT-proADM 有权
    通过确定标记CT-proADM进行诊断和危险分层

    公开(公告)号：US08436135B2

    公开(公告)日：2013-05-07

    申请号：US12520159

    申请日：2007-12-20

    申请人： Andreas Bergmann ,  Joachim Struck

    发明人： Andreas Bergmann ,  Joachim Struck

    IPC分类号： A61K38/00

    CPC分类号： G01N33/6884 ,  C07K14/47 ,  C07K14/575 ,  C07K16/26 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/47 ,  G01N2800/12 ,  G01N2800/32

    摘要： The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No, 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method.

    摘要翻译： 本发明涉及用于诊断和/或分层疾病风险的新型诊断标记物CT-proADM（preproADM的C末端片段，SEQ ID NO：1）。 还公开了用于诊断和/或分层疾病，特别是心血管疾病，心脏功能不全以及肺和呼吸道的感染和/或炎症的风险的方法。 在所述方法中，在待检查的患者中确定CT-proADM（SEQ ID No.1）标记或其片段的部分肽或包含在标记组合（面板，群集）中的所述标记。 本发明还涉及诊断装置以及用于执行所述方法的套件。

    Antibodies for the selective determination of procalcitonin 1-116
    29.
    发明授权
    Antibodies for the selective determination of procalcitonin 1-116 有权
    用于选择性测定降钙素原的抗体1-116

    公开(公告)号：US08354506B2

    公开(公告)日：2013-01-15

    申请号：US12529089

    申请日：2008-02-21

    申请人： Andreas Bergmann ,  Joachim Struck

    发明人： Andreas Bergmann ,  Joachim Struck

    IPC分类号： C07K16/26

    CPC分类号： G01N33/6854 ,  C07K16/26 ,  C07K2317/34 ,  G01N33/74 ,  G01N2333/585

    摘要： The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient for diagnostic purposes, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of procalcitonin, or procalcitonin partial peptides derived therefrom, having the amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116 (SEQ ID NO: 1.) Also disclosed are antibodies and kits for carrying out such a method.

    摘要翻译： 本发明提供了用于诊断目的的用于确定患者生物样品中的降钙素原和降钙素原衍生物的免疫诊断方法，特别是在监测和控制治疗以及监测局部或全身细菌感染，炎症，败血症 或神经变性疾病。 特别地，该方法检测在完全降钙素原1-116（SEQ ID NO：1）的氨基末端位置1和2中具有氨基酸丙氨酸和脯氨酸（Ala-Pro，AP）的降钙素原或降钙素原部分肽的分子形式 ID NO：1）还公开了用于进行这种方法的抗体和试剂盒。

    In vitro method for the detection of early-stage liver damage
    30.
    发明授权
    In vitro method for the detection of early-stage liver damage 有权
    用于检测早期肝损伤的体外方法

    公开(公告)号：US08252548B2

    公开(公告)日：2012-08-28

    申请号：US12299829

    申请日：2007-05-08

    申请人： Andreas Bergmann ,  Joachim Struck ,  Nils G. Morgenthaler

    发明人： Andreas Bergmann ,  Joachim Struck ,  Nils G. Morgenthaler

    IPC分类号： C12Q1/34

    CPC分类号： G01N33/6893 ,  G01N2800/085

    摘要： Disclosed is an in vitro method for the identification and the concomitant monitoring of the therapy and cure of drug-induced or addictive substance-induced liver damage, in which the occurrence of the human enzyme carbamoyl synthase 1 (CPS 1) or its concentration is determined in serum or plasma samples from patients who are being or have been treated with potentially liver-damaging drugs, or from people who take harmful stimulants and addictive substances or are exposed to hepatotoxic substances.

    摘要翻译： 公开了一种用于鉴定和伴随监测药物诱导或成瘾物质诱导的肝损伤的治疗和治疗的体外方法，其中确定人酶氨基甲酰合酶1（CPS 1）或其浓度的发生 来自患有或已经被潜在的肝损伤药物治疗的患者的血清或血浆样品，或者来自服用有害兴奋剂和成瘾物质或暴露于肝毒性物质的人。